Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma
Simeng Hu, … , Fan Bai, Zhi Wang
Simeng Hu, … , Fan Bai, Zhi Wang
Published August 16, 2022
Citation Information: J Clin Invest. 2022;132(19):e157649. https://doi.org/10.1172/JCI157649.
View: Text | PDF
Research Article Immunology Oncology Article has an altmetric score of 10

TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma

  • Text
  • PDF
Abstract

Characterization of the dynamic change in the immunological landscape during malignant transformation from precancerous lesions to cancerous lesions in squamous cell carcinoma (SCC) is critical for the application of immunotherapy. Here, we performed single-cell RNA-Seq (scRNA-Seq) of 131,702 cells from 13 cancerous tissues of oral squamous cell carcinoma (OSCC), 3 samples of precancerous oral leukoplakia, and 8 adjacent normal samples. We found that tumor-infiltrating CD4+ and CD8+ T cells were functionally inhibited by immunosuppressive ligands expressed on various types of myeloid cells or neutrophils in the process of oral carcinogenesis. Notably, we identified a subset of myofibroblasts that exclusively expressed tryptophan 2,3-dioxygenase (TDO2). These TDO2+ myofibroblasts were located distally from tumor nests, and both CD4+ and CD8+ T cells were enriched around them. Functional experiments revealed that TDO2+ myofibroblasts were more likely to possess the ability for chemotaxis toward T cells but induced the transformation of CD4+ T cells into Tregs and caused CD8+ T cell dysfunction. We further showed that use of the TDO2 inhibitor LM10 attenuated the inhibitory states of T cells, restored the T cell antitumor response, and prevented the progression of OSCC malignant transformation in murine models. Our study reveals a multistep transcriptomic landscape of OSCC and demonstrates that TDO2+ myofibroblasts are potential targets for immunotherapy.

Authors

Simeng Hu, Huanzi Lu, Wenqiang Xie, Dikan Wang, Zhongyan Shan, Xudong Xing, Xiang-Ming Wang, Juan Fang, Wei Dong, Wenxiao Dai, Junyi Guo, Yanshu Zhang, Shuqiong Wen, Xin-Yu Guo, Qianming Chen, Fan Bai, Zhi Wang

×

Figure 4

Subsets of ADSC-Fibro-MF cells and a subtype of myofibroblasts expressing TDO2 in OSCC.

Options: View larger image (or click on image) Download as PowerPoint
Subsets of ADSC-Fibro-MF cells and a subtype of myofibroblasts expressin...
(A) UMAP plot showing the distribution of ADSC-Fibro-MF subsets, with each color representing a cell subset. (B) Bar plots showing the percentage of ADSC-Fibro-MF subsets among total ADSC-Fibro-MF cells in adjacent normal, OLK, and OSCC tissues. *P < 0.05,**P < 0.01, and ****P < 0.0001, by Kruskal-Wallis test followed by Bonferroni’s multiple-comparison test. (C) Volcano plot showing differentially expressed genes between MF-C1-TDO2 and MF-C2-ELN. Red dots represent genes that were significantly upregulated in MF-C1-TDO2 [log2(fold change) >1, adjusted P < 0.05]; blue dots represent genes that were significantly upregulated in MF-C2-ELN [log2(fold change) <–1, adjusted P < 0.05]; and gray dots represent genes with no significant difference. (D) Bar plot showing the top 15 highest differential pathways between MF-C1-TDO2 and MF-C2-ELN. Red bars represent pathways that were enriched in MF-C1-TDO2, and blue bars represent pathways that were enriched in MF-C2-ELN. (E) Violin plot showing the score for the AhR activation module among ADSC-Fibro-MF subsets. ****P < 0.0001, by Wilcoxon rank-sum test. (F) IF staining images showing the expression intensity of α-SMA (green) and TDO2 (red) in OSCC and normal adjacent tissue. Images in the first row were obtained at ×10 magnification (scale bars: 200 μm). Images in the second row were obtained at ×40 magnification (scale bars: 10 μm). (G) UMAP plot showing the differentiation trajectory of ADSC-Fibro-MF cells and the distribution of each cell subset on the trajectory. Branch 1 is mainly composed of ADSCs, branch 2 is mainly composed of fibroblasts, and branch 3 is mainly composed of myofibroblasts. The numbers indicate the branches.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 4 X users
49 readers on Mendeley
See more details